Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy Mukherjee K; Chakravarthy AB; Goff LW; El-Rifai WDig Dis Sci 2010[Dec]; 55 (12): 3304-14Esophageal adenocarcinoma is an aggressive malignancy with a poor outcome, and its incidence continues to rise at an alarming rate. Current treatment strategies combining chemotherapy, radiation, and surgery are plagued with high rates of recurrence and metastasis. Multiple molecular pathways including the epidermal growth factor receptor, vascular endothelial growth factor, v-erb-b2 erythroblastic leukemia viral oncogene homolog (ERBB2), and Aurora kinase pathways are activated in many esophageal adenocarcinomas. In many cases, these pathways have critical roles in tumor progression. Research on the mechanisms by which these pathways contribute to disease progression has resulted in numerous biologic agents and small molecules with the potential to improve outcome. The promise of targeted therapy and personalized medicine in improving the clinical outcome is now closer than it has ever been.|*Molecular Targeted Therapy/methods/trends[MESH]|Adenocarcinoma/*drug therapy/mortality/physiopathology/therapy[MESH]|Angiogenesis Inhibitors/pharmacology[MESH]|Antineoplastic Agents/pharmacology[MESH]|Aurora Kinases[MESH]|Barrett Esophagus/pathology[MESH]|Clinical Trials as Topic[MESH]|Combined Modality Therapy[MESH]|Disease Progression[MESH]|ErbB Receptors/antagonists & inhibitors/drug effects/physiology[MESH]|Esophageal Neoplasms/*drug therapy/mortality/physiopathology/therapy[MESH]|Esophagectomy[MESH]|Humans[MESH]|Protein Serine-Threonine Kinases/antagonists & inhibitors/pharmacology[MESH]|Treatment Outcome[MESH] |
